Robust affiliation between malnutrition, irritation, and atherosclerosis in power renal failure.
Background
Atheroscleroticcardiovascular illness and malnutrition are widely known as main causes of the elevated morbidity and mortality noticed in uremic sufferers. C-reactive protein (CRP), an acute-phase protein, is a predictor of cardiovascular mortality in nonrenal affected person populations. In power renal failure (CRF), the prevalence of an acute-phase response has been related to an elevated mortality.
METHODS
100 and 9 predialysis sufferers (age 52 +/- 1 years) with terminal CRF (glomerular filtration charge 7 +/- 1 ml/min) have been studied. Through the use of noninvasive B-mode ultrasonography, the cross-sectional carotid intima-media space was calculated, and the presence or absence of carotid plaques was decided.
Dietary standing was assessed by subjective world evaluation (SGA), dual-energy x-ray absorptiometry (DXA), serum albumin, serum creatinine, serum urea, and 24-hour urine urea excretion. The presence of an inflammatory response was assessed by CRP, fibrinogen (N = 46), and tumor necrosis factor-alpha (TNF-alpha; N = 87). Lipid parameters, together with Lp(a) and apo(a)-isoforms, in addition to markers of oxidative stress (autoantibodies in opposition to oxidized low-density lipoprotein and vitamin E), have been additionally decided.
RESULTS
In contrast with wholesome controls, CRF sufferers had an elevated imply carotid intima-media space (18.3 +/- 0.6 vs. 13.2 +/- 0.7 mm2, P < 0.0001) and a better prevalence of carotid plaques (72 vs. 32%, P = 0.001). The prevalence of malnutrition (SGA 2 to 4) was 44%, and 32% of all sufferers had an acute-phase response (CRP>> or = 10 mg/liter).
Malnourished sufferers had larger CRP ranges (23 +/- Three vs. 13 +/- 2 mg/liter, P < 0.01), elevated calculated intima-media space (20.2 +/- 0.eight vs. 16.9 +/- 0.7 mm2, P < 0.01) and a better prevalence of carotid plaques (90 vs. 60%, P < 0.0001) in contrast with well-nourished sufferers.
Throughout stepwise multivariate evaluation adjusting for age and gender, vitamin E (P < 0.05) and CRP (P < 0.05) remained related to an elevated intima-media space. The presence of carotid plaques was considerably related to age (P < 0.001), log oxidized low-density lipoprotein (oxLDL; P < 0.01), and small apo(a) isoform dimension (P < 0.05) in a multivariate logistic regression mannequin.

CONCLUSIONS
These outcomes point out that the quickly growing atherosclerosis in superior CRF seems to be attributable to a synergism of various mechanisms, similar to malnutrition, irritation, oxidative stress, and genetic parts. Aside from basic danger components, low vitamin E ranges and elevated CRP ranges are related to an elevated intima-media space, whereas small molecular weight apo(a) isoforms and elevated ranges of oxLDL are related to the presence of carotid plaques.
GPR61 Antibody |
|||
DF2755 | Affbiotech | 200ul | EUR 420 |
GPR61 Antibody |
|||
DF2810 | Affbiotech | 200ul | EUR 420 |
GPR61 Polyclonal Antibody |
|||
ABP58695-003ml | Abbkine | 0.03ml | EUR 189.6 |
Description: A polyclonal antibody for detection of GPR61 from Human, Mouse. This GPR61 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human GPR61 protein at amino acid sequence of 190-270 |
GPR61 Polyclonal Antibody |
|||
ABP58695-01ml | Abbkine | 0.1ml | EUR 346.8 |
Description: A polyclonal antibody for detection of GPR61 from Human, Mouse. This GPR61 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human GPR61 protein at amino acid sequence of 190-270 |
GPR61 Polyclonal Antibody |
|||
ABP58695-02ml | Abbkine | 0.2ml | EUR 496.8 |
Description: A polyclonal antibody for detection of GPR61 from Human, Mouse. This GPR61 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human GPR61 protein at amino acid sequence of 190-270 |
GPR61 Conjugated Antibody |
|||
C44933 | SAB | 100ul | EUR 476.4 |
GPR61 Polyclonal Antibody |
|||
ES11477-100ul | ELK Biotech | 100ul | EUR 334.8 |
Description: A Rabbit Polyclonal antibody against GPR61 from Human/Mouse. This antibody is tested and validated for WB, ELISA, WB, ELISA |
GPR61 Polyclonal Antibody |
|||
ES11477-50ul | ELK Biotech | 50ul | EUR 248.4 |
Description: A Rabbit Polyclonal antibody against GPR61 from Human/Mouse. This antibody is tested and validated for WB, ELISA, WB, ELISA |
GPR61 siRNA |
|||
20-abx918539 | Abbexa |
|
|
GPR61 siRNA |
|||
20-abx918540 | Abbexa |
|
|
GPR61 Recombinant Protein (Human) |
|||
RP013882 | ABM | 100 ug | Ask for price |
GPR61 Recombinant Protein (Rat) |
|||
RP203447 | ABM | 100 ug | Ask for price |
GPR61 Recombinant Protein (Mouse) |
|||
RP139673 | ABM | 100 ug | Ask for price |
GPR61 cloning plasmid |
|||
CSB-CL866330HU-10ug | Cusabio | 10ug | EUR 279.6 |
Description: A cloning plasmid for the GPR61 gene. |
GPR61 Blocking Peptide |
|||
DF2755-BP | Affbiotech | 1mg | EUR 234 |
GPR61 Blocking Peptide |
|||
DF2810-BP | Affbiotech | 1mg | EUR 234 |
Polyclonal GPR61 Antibody (C-Terminus) |
|||
APR16588G | Leading Biology | 0.05mg | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (C-Terminus). This antibody is tested and proven to work in the following applications: |
Polyclonal GPR61 Antibody (C-Terminus) |
|||
APR16589G | Leading Biology | 0.05mg | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (C-Terminus). This antibody is tested and proven to work in the following applications: |
Polyclonal GPR61 Antibody (Cytoplasmic Domain) |
|||
APR16590G | Leading Biology | 0.05mg | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (Cytoplasmic Domain). This antibody is tested and proven to work in the following applications: |
Polyclonal GPR61 Antibody (Extracellular Domain) |
|||
APR16591G | Leading Biology | 0.05mg | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (Extracellular Domain). This antibody is tested and proven to work in the following applications: |
Polyclonal GPR61 Antibody (N-Terminus) |
|||
APR16592G | Leading Biology | 0.05mg | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR61 (N-Terminus). This antibody is tested and proven to work in the following applications: |
Polyclonal Goat anti-GST α-form |
|||
GST-ANTI-1 | Detroit R&D | 50 uL | EUR 336 |
Polyclonal Goat anti-GST μ-form |
|||
GST-ANTI-2 | Detroit R&D | 50 uL | EUR 336 |
Polyclonal Goat anti-GST p-form |
|||
GST-ANTI-3 | Detroit R&D | 50 uL | EUR 336 |
Human GPR61 shRNA Plasmid |
|||
20-abx963213 | Abbexa |
|
|
Mouse GPR61 shRNA Plasmid |
|||
20-abx981729 | Abbexa |
|
|
Probable G-Protein Coupled Receptor 61 (GPR61) Antibody |
|||
20-abx147479 | Abbexa |
|
|
Probable G-Protein Coupled Receptor 61 (GPR61) Antibody |
|||
abx147480-100ug | Abbexa | 100 ug | EUR 526.8 |
Gpr61 ORF Vector (Rat) (pORF) |
|||
ORF067817 | ABM | 1.0 ug DNA | EUR 607.2 |
GPR61 ORF Vector (Human) (pORF) |
|||
ORF004628 | ABM | 1.0 ug DNA | EUR 114 |
Gpr61 ORF Vector (Mouse) (pORF) |
|||
ORF046559 | ABM | 1.0 ug DNA | EUR 607.2 |
GPR61 Protein Vector (Human) (pPB-C-His) |
|||
PV018509 | ABM | 500 ng | EUR 394.8 |
GPR61 Protein Vector (Human) (pPB-N-His) |
|||
PV018510 | ABM | 500 ng | EUR 394.8 |
GPR61 Protein Vector (Human) (pPM-C-HA) |
|||
PV018511 | ABM | 500 ng | EUR 394.8 |
GPR61 Protein Vector (Human) (pPM-C-His) |
|||
PV018512 | ABM | 500 ng | EUR 394.8 |
GPR61 Protein Vector (Mouse) (pPB-C-His) |
|||
PV186234 | ABM | 500 ng | EUR 723.6 |
GPR61 Protein Vector (Mouse) (pPB-N-His) |
|||
PV186235 | ABM | 500 ng | EUR 723.6 |
GPR61 Protein Vector (Mouse) (pPM-C-HA) |
|||
PV186236 | ABM | 500 ng | EUR 723.6 |
GPR61 Protein Vector (Mouse) (pPM-C-His) |
|||
PV186237 | ABM | 500 ng | EUR 723.6 |
GPR61 Protein Vector (Rat) (pPB-C-His) |
|||
PV271266 | ABM | 500 ng | EUR 723.6 |
GPR61 Protein Vector (Rat) (pPB-N-His) |
|||
PV271267 | ABM | 500 ng | EUR 723.6 |
GPR61 Protein Vector (Rat) (pPM-C-HA) |
|||
PV271268 | ABM | 500 ng | EUR 723.6 |
GPR61 Protein Vector (Rat) (pPM-C-His) |
|||
PV271269 | ABM | 500 ng | EUR 723.6 |
GPR61 sgRNA CRISPR Lentivector set (Human) |
|||
K0892201 | ABM | 3 x 1.0 ug | EUR 406.8 |
Gpr61 sgRNA CRISPR Lentivector set (Rat) |
|||
K6526201 | ABM | 3 x 1.0 ug | EUR 406.8 |
Gpr61 sgRNA CRISPR Lentivector set (Mouse) |
|||
K3882801 | ABM | 3 x 1.0 ug | EUR 406.8 |
GPR61 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
K0892202 | ABM | 1.0 ug DNA | EUR 184.8 |
GPR61 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
K0892203 | ABM | 1.0 ug DNA | EUR 184.8 |
GPR61 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
K0892204 | ABM | 1.0 ug DNA | EUR 184.8 |
Gpr61 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
K6526202 | ABM | 1.0 ug DNA | EUR 184.8 |
Gpr61 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
K6526203 | ABM | 1.0 ug DNA | EUR 184.8 |
Gpr61 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
K6526204 | ABM | 1.0 ug DNA | EUR 184.8 |
Gpr61 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
K3882802 | ABM | 1.0 ug DNA | EUR 184.8 |
Gpr61 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
K3882803 | ABM | 1.0 ug DNA | EUR 184.8 |
Gpr61 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
K3882804 | ABM | 1.0 ug DNA | EUR 184.8 |
GPR61 3'UTR Luciferase Stable Cell Line |
|||
TU009173 | ABM | 1.0 ml | EUR 1825.2 |
Gpr61 3'UTR GFP Stable Cell Line |
|||
TU255385 | ABM | 1.0 ml | Ask for price |
GPR61 3'UTR GFP Stable Cell Line |
|||
TU059173 | ABM | 1.0 ml | EUR 1825.2 |
Gpr61 3'UTR Luciferase Stable Cell Line |
|||
TU205385 | ABM | 1.0 ml | Ask for price |
Gpr61 3'UTR Luciferase Stable Cell Line |
|||
TU109034 | ABM | 1.0 ml | Ask for price |
Gpr61 3'UTR GFP Stable Cell Line |
|||
TU159034 | ABM | 1.0 ml | Ask for price |
Mouse Probable G- protein coupled receptor 61, Gpr61 ELISA KIT |
|||
ELI-31707m | Lifescience Market | 96 Tests | EUR 1038 |
Human Probable G- protein coupled receptor 61, GPR61 ELISA KIT |
|||
ELI-32663h | Lifescience Market | 96 Tests | EUR 988.8 |
GPR61 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
K0892205 | ABM | 3 x 1.0 ug | EUR 451.2 |
Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
K6526205 | ABM | 3 x 1.0 ug | EUR 451.2 |
Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
K3882805 | ABM | 3 x 1.0 ug | EUR 451.2 |
GPR61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
K0892206 | ABM | 1.0 ug DNA | EUR 200.4 |
GPR61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
K0892207 | ABM | 1.0 ug DNA | EUR 200.4 |
GPR61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
K0892208 | ABM | 1.0 ug DNA | EUR 200.4 |
Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
K6526206 | ABM | 1.0 ug DNA | EUR 200.4 |
Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
K6526207 | ABM | 1.0 ug DNA | EUR 200.4 |
Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
K6526208 | ABM | 1.0 ug DNA | EUR 200.4 |
Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
K3882806 | ABM | 1.0 ug DNA | EUR 200.4 |
Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
K3882807 | ABM | 1.0 ug DNA | EUR 200.4 |
Gpr61 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
K3882808 | ABM | 1.0 ug DNA | EUR 200.4 |
Anti-PML Protein Antibody |
|||
PB10084 | BosterBio | 100ug/vial | EUR 400.8 |
Anti-PML Protein Antibody |
|||
PB10085 | BosterBio | 100ug/vial | EUR 400.8 |
Anti-Protein Z antibody |
|||
STJ98340 | St John's Laboratory | 100 µl | EUR 280.8 |
Description: Mouse monoclonal to Protein Z. |
Anti-Protein C antibody |
|||
STJ96586 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to Protein C. |
Anti-Random protein antibody |
|||
STJ140013 | St John's Laboratory | 150 µg | EUR 262.8 |
Description: Goat polyclonal antibody to Random recombinant protein fragment. This Random recombinant protein fragment does not have any homology to known protein sequence. This antibody can be used in biochemical and cell biology experiments as a negative control. |
Anti-ALK Protein antibody |
|||
STJ16100308 | St John's Laboratory | 1 mL | EUR 1594.8 |
Anti-CutA protein antibody |
|||
STJ73349 | St John's Laboratory | 100 µg | EUR 430.8 |
Anti-Protein Vestigial Antibody |
|||
STJ503515 | St John's Laboratory | 100 µg | EUR 571.2 |
Malnutrition-inflammation complicated syndrome in dialysis sufferers: causes and penalties.
Atherosclerotic heart problems and malnutrition are widely known as main causes of the elevated morbidity and mortality noticed in uremic sufferers. C-reactive protein (CRP), an acute-phase protein, is a predictor of cardiovascular mortality in nonrenal affected person populations. In power renal failure (CRF), the prevalence of an acute-phase response has been related to an elevated mortality.
METHODS
100 and 9 predialysis sufferers (age 52 +/- 1 years) with terminal CRF (glomerular filtration charge 7 +/- 1 ml/min) have been studied. Through the use of noninvasive B-mode ultrasonography, the cross-sectional carotid intima-media space was calculated, and the presence or absence of carotid plaques was decided.
Dietary standing was assessed by subjective world evaluation (SGA), dual-energy x-ray absorptiometry (DXA), serum albumin, serum creatinine, serum urea, and 24-hour urine urea excretion.
The presence of an inflammatory response was assessed by CRP, fibrinogen (N = 46), and tumor necrosis factor-alpha (TNF-alpha; N = 87). Lipid parameters, together with Lp(a) and apo(a)-isoforms, in addition to markers of oxidative stress (autoantibodies in opposition to oxidized low-density lipoprotein and vitamin E), have been additionally decided.
RESULTS
In contrast with wholesome controls, CRF sufferers had an elevated imply carotid intima-media space (18.3 +/- 0.6 vs. 13.2 +/- 0.7 mm2, P < 0.0001) and a better prevalence of carotid plaques (72 vs. 32%, P = 0.001). The prevalence of malnutrition (SGA 2 to 4) was 44%, and 32% of all sufferers had an acute-phase response (CRP>> or = 10 mg/liter).
Malnourished sufferers had larger CRP ranges (23 +/- Three vs. 13 +/- 2 mg/liter, P < 0.01), elevated calculated intima-media space (20.2 +/- 0.eight vs. 16.9 +/- 0.7 mm2, P < 0.01) and a better prevalence of carotid plaques (90 vs. 60%, P < 0.0001) in contrast with well-nourished sufferers.
Throughout stepwise multivariate evaluation adjusting for age and gender, vitamin E (P < 0.05) and CRP (P < 0.05) remained related to an elevated intima-media space. The presence of carotid plaques was considerably related to age (P < 0.001), log oxidized low-density lipoprotein (oxLDL; P < 0.01), and small apo(a) isoform dimension (P < 0.05) in a multivariate logistic regression mannequin.
CONCLUSIONS
These outcomes point out that the quickly growing atherosclerosis in superior CRF seems to be attributable to a synergism of various mechanisms, similar to malnutrition, irritation, oxidative stress, and genetic parts. Aside from basic danger components, low vitamin E ranges and elevated CRP ranges are related to an elevated intima-media space, whereas small molecular weight apo(a) isoforms and elevated ranges of oxLDL are related to the presence of carotid plaques.
- Protein-energy malnutrition (PEM) and irritation are widespread and often concurrent in upkeep dialysis sufferers. Many components that seem to result in these 2 situations overlap, as do evaluation instruments and such standards for detecting them as hypoalbuminemia.
- Each these situations are associated to poor dialysis end result. Low urge for food and a hypercatabolic state are amongst widespread options. PEM in dialysis sufferers has been advised to be secondary to irritation; nonetheless, the proof isn’t conclusive, and an equicausal standing and even reverse causal route is feasible.
- Therefore, malnutrition-inflammation complicated syndrome (MICS) is an applicable time period. Attainable causes of MICS embody comorbid diseases, oxidative and carbonyl stress, nutrient loss by means of dialysis, anorexia and low nutrient consumption, uremic toxins, decreased clearance of inflammatory cytokines, quantity overload, and dialysis-related components.
- MICS is believed to be the primary reason behind erythropoietin hyporesponsiveness, excessive charge of cardiovascular atherosclerotic illness, decreased high quality of life, and elevated mortality and hospitalization in dialysis sufferers.
- As a result of MICS results in a low physique mass index, hypocholesterolemia, hypocreatininemia, and hypohomocysteinemia, a “reverse epidemiology” of cardiovascular dangers can happen in dialysis sufferers.
- Due to this fact, weight problems, hypercholesterolemia, and elevated blood ranges of creatinine and homocysteine look like protecting and paradoxically related to a greater end result.
- There isn’t a consensus about tips on how to decide the diploma of severity of MICS or tips on how to handle it. A number of diagnostic instruments and therapy modalities are mentioned. Profitable administration of MICS might ameliorate the cardiovascular epidemic and poor end result in dialysis sufferers.
- Scientific trials specializing in MICS and its doable causes and penalties are urgently required to enhance poor medical end result in dialysis sufferers.
Recombinant EBV EBNA1 Mosaic Protein, His, E.coli-100ug |
|||
QP11732-100ug | EnQuireBio | 100ug | EUR 261.6 |
Recombinant EBV EBNA1 Mosaic Protein, His, E.coli-1mg |
|||
QP11732-1mg | EnQuireBio | 1mg | EUR 1273.2 |
Recombinant EBV EBNA1 Mosaic Protein, His, E.coli-500ug |
|||
QP11732-500ug | EnQuireBio | 500ug | EUR 795.6 |
EBNA1 protein |
|||
30-1925 | Fitzgerald | 500 ug | EUR 678 |
Description: Purified Recombinant EBNA1 protein |
Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [His] |
|||
VAng-2528Lsx-100g | Creative Biolabs | 100 µg | EUR 555.6 |
Description: EBV EBNA1 Mosaic protein, His tag at C-terminus, recombinant protein from E. coli. |
Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [His] |
|||
VAng-2528Lsx-1mg | Creative Biolabs | 1 mg | EUR 3360 |
Description: EBV EBNA1 Mosaic protein, His tag at C-terminus, recombinant protein from E. coli. |
Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [His] |
|||
VAng-2528Lsx-500g | Creative Biolabs | 500 µg | EUR 2040 |
Description: EBV EBNA1 Mosaic protein, His tag at C-terminus, recombinant protein from E. coli. |
Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [GST] |
|||
VAng-Lsx0111-100g | Creative Biolabs | 100 µg | EUR 759.6 |
Description: EBV EBNA1 Mosaic protein [GST], recombinant protein from E. coli. |
Recombinant EBV EBNA1 Mosaic Protein (aa 1-90 & 408-498) [GST] |
|||
VAng-Lsx0111-500g | Creative Biolabs | 500 µg | EUR 2419.2 |
Description: EBV EBNA1 Mosaic protein [GST], recombinant protein from E. coli. |
pCXWB- EBNA1 |
|||
PVT10196 | Lifescience Market | 2 ug | EUR 361.2 |
Recombinant (E.Coli, GST tag) Epstein-Barr Virus (EBV/HHV-4) Mosaic EBNA1 |
|||
RP-347 | Alpha Diagnostics | 100 ug | EUR 343.2 |
EBNA1 protein (His tag) |
|||
80-1340 | Fitzgerald | 100 ug | EUR 289.2 |
Description: Purified recombinant EBNA1 protein (His tag) |
Recombinant EBNA1 Protein [GST] |
|||
VAng-Lsx0122-100g | Creative Biolabs | 100 µg | EUR 818.4 |
Description: EBNA1 (EBV) (P03211) partial recombinant protein with GST tag expressed in E. coli. |
EBV protein |
|||
30-1275 | Fitzgerald | 1 mg | EUR 4177.2 |
Description: Purified recombinant EBV protein |
EBV protein |
|||
30-1276 | Fitzgerald | 1 mg | EUR 4177.2 |
Description: Purified recombinant EBV protein |
EBV Protein |
|||
abx069822-1ml | Abbexa | 1 ml | EUR 828 |
EBV Protein |
|||
abx069824-1mg | Abbexa | 1 mg | EUR 1762.8 |
EBV Protein |
|||
abx069825-1ml | Abbexa | 1 ml | EUR 376.8 |
EBV Protein |
|||
abx069828-1mg | Abbexa | 1 mg | EUR 2180.4 |
EBV Protein |
|||
abx069829-1mg | Abbexa | 1 mg | EUR 2131.2 |
EBNA1 Binding Protein 2 Protein |
|||
20-abx260778 | Abbexa |
|
|
pCXWB- EBNA1 Plasmid |
|||
PVT7175 | Lifescience Market | 2 ug | EUR 319.2 |
EBV EA protein |
|||
30R-AE005 | Fitzgerald | 100 ug | EUR 392.4 |
Description: Purified recombinant EBV EA protein |
EBV p18 protein |
|||
30R-AE007 | Fitzgerald | 500 ug | EUR 967.2 |
Description: Purified recombinant EBV p18 protein |
EBV p23 protein |
|||
30R-AE008 | Fitzgerald | 100 ug | EUR 392.4 |
Description: Purified recombinant EBV p23 protein |
EBV EA protein |
|||
30-1280 | Fitzgerald | 1 mg | EUR 4177.2 |
Description: Purified recombinant EBV EA protein |
EBV VCA protein |
|||
30-1811 | Fitzgerald | 1 ml | EUR 457.2 |
Description: Purified native EBV VCA gp125 protein |
EBV EA protein |
|||
30-1920 | Fitzgerald | 1 ml | EUR 496.8 |
Description: Viral lysate containing a high concentration of EBV antigens, including VCA, EBNA, EA-D and EA-R |
EBV EBNA protein |
|||
30-AE46 | Fitzgerald | 200 ug | EUR 900 |
Description: Purified recombinant EBV EBNA protein |
EBV EA protein |
|||
30-AE50 | Fitzgerald | 200 ug | EUR 975.6 |
Description: Purified recombinant EBV EA protein |
Recombinant EBV Protein |
|||
VAng-Lsx0108-inquire | Creative Biolabs | inquire | Ask for price |
Description: EBV, recombinant protein from human cells. |
EBNA1 (GFP-Puro) Lentivirus |
|||
LVP1134-GP | GenTarget | 1x107 IFU/ml x 200ul | EUR 418.8 |
Description: Premade lentivirus expressing Epstein Barr Virus' EBNA1 gene under EF1a promoter, containing GFP-Puromycin dual marker. |
EBNA1 (RFP-Bsd) Lentivirus |
|||
LVP1134-RB | GenTarget | 1x107 IFU/ml x 200ul | EUR 418.8 |
Description: Premade lentivirus expressing Epstein Barr Virus' EBNA1 gene under EF1a promoter, containing RFP-Blasticidin dual marker. |
EBNA1 Binding Protein 2 (EBNA1BP2) Antibody |
|||
20-abx123650 | Abbexa |
|
|
EBNA1 Binding Protein 2 (EBNA1BP2) Antibody |
|||
abx026949-400ul | Abbexa | 400 ul | EUR 627.6 |
EBNA1 Binding Protein 2 (EBNA1BP2) Antibody |
|||
abx026949-80l | Abbexa | 80 µl | EUR 343.2 |
EBV [His] |
|||
DAG1578 | Creative Diagnostics | 100 µg | EUR 972 |
EBV [GST] |
|||
DAG1580 | Creative Diagnostics | 100 µg | EUR 774 |
EBV [GST] |
|||
DAG1581 | Creative Diagnostics | 100 µg | EUR 972 |
EBV [His] |
|||
DAG1584 | Creative Diagnostics | 100 µg | EUR 972 |
EBV antibody |
|||
10-E40C | Fitzgerald | 200 ug | EUR 274.8 |
Description: Mouse monoclonal EBV antibody |
EBV antibody |
|||
10-E40D | Fitzgerald | 200 ug | EUR 163.2 |
Description: Mouse monoclonal EBV antibody |
EBV antibody |
|||
10-E40E | Fitzgerald | 200 ug | EUR 254.4 |
Description: Mouse monoclonal EBV antibody |
EBV Virus |
|||
G229 | ABM | 10 ml | EUR 882 |
EBV P18 Mosaic protein |
|||
DAG1582 | Creative Diagnostics | 100 µg | EUR 774 |
EBV VCA p23 Protein |
|||
abx069823-1mg | Abbexa | 1 mg | EUR 1796.4 |
Recombinant EBV Protein [His] |
|||
VAng-Lsx0112-inquire | Creative Biolabs | inquire | Ask for price |
Description: EBV [His], recombinant protein from E. coli. |
Recombinant EBV P125 Protein |
|||
VAng-Lsx0119-1mL | Creative Biolabs | 1 mL | EUR 465.6 |
Description: EBV P125 Protein, recombinant protein from E. coli. |
Recombinant EBV P125 Protein |
|||
VAng-Lsx0119-25mL | Creative Biolabs | 25 mL | EUR 7318.8 |
Description: EBV P125 Protein, recombinant protein from E. coli. |
Epstein-Barr Virus (HHV-4) EBNA1 Protein |
|||
20-abx260340 | Abbexa |
|
|
Recombinant EBNA1 Protein [His] (1.185 mg/mL) |
|||
VAng-0610Lsx-inquire | Creative Biolabs | inquire | Ask for price |
Description: Epstein-Barr Virus (EBV) Nuclear Antigen-1 (EBNA-1), recombinant protein from E. coli. MW 63 kDa, 1.185 mg/mL. |
Recombinant EBNA1 Protein [His] (1.25 mg/mL) |
|||
VAng-0611Lsx-inquire | Creative Biolabs | inquire | Ask for price |
Description: Epstein-Barr Virus (EBV) Nuclear Antigen-1 (EBNA-1), recombinant protein from E. coli. MW 63 kDa, 1.25 mg/mL. |
EBNA1BP2 EBNA1 Binding Protein 2 Human Recombinant Protein |
|||
PROTQ99848 | BosterBio | Regular: 20ug | EUR 380.4 |
Description: Recombinant Human EBNA1BP2 produced in E. coli is a single polypeptide chain containing 329 amino acids (1-306) and having a molecular mass of 37.2kDa.;EBNA1BP2 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
EBV HHV-4 p23 Protein |
|||
abx060518-1mg | Abbexa | 1 mg | EUR 2264.4 |
EBV p54 (EA-D) Protein |
|||
abx061433-1mg | Abbexa | 1 mg | EUR 1813.2 |
EBV p18 protein (His tag) |
|||
80-1355S | Fitzgerald | 100 ug | EUR 289.2 |
Description: Purified recombinant EBV p18 protein (His tag) |
EBV p54 protein (His tag) |
|||
80-1361 | Fitzgerald | 1 mg | EUR 1299.6 |
Description: Purified recombinant EBV p54 protein (His tag) |
EBV p138 protein (His tag) |
|||
80-1362 | Fitzgerald | 1 mg | EUR 1299.6 |
Description: Purified recombinant EBV p138 protein (His tag) |
Recombinant EBV P138 Protein [His] |
|||
VAng-0612Lsx-inquire | Creative Biolabs | inquire | Ask for price |
Description: EBV p138 Early Antigen D (EA-D) Protein, recombinant protein from E. coli. 1.00 mg/mL. |
Recombinant EBV P54 Protein [His] |
|||
VAng-0613Lsx-inquire | Creative Biolabs | inquire | Ask for price |
Description: EBV p54 Early Antigen D (EA-D) Protein, recombinant protein from E. coli. 1.068 mg/mL. |
Recombinant EBV P18 Protein [His] |
|||
VAng-0614Lsx-inquire | Creative Biolabs | inquire | Ask for price |
Description: EBV Viral Capsid Antigen (VCA) p18, recombinant protein from E. coli. 2.14 mg/mL. |
Recombinant EBV p23 Protein [GST] |
|||
VAng-0617Lsx-inquire | Creative Biolabs | inquire | Ask for price |
Description: EBV p23, recombinant protein from E. coli. 1.00 mg/mL. |
Recombinant EBV P18 Mosaic Protein |
|||
VAng-Lsx0115-inquire | Creative Biolabs | inquire | Ask for price |
Description: EBV P18 Mosaic protein, recombinant protein from E. coli. |
Recombinant EBV P23 Protein [His] |
|||
VAng-Lsx0117-inquire | Creative Biolabs | inquire | Ask for price |
Description: Recombinant EBV p23 protein was expressed in E. coli and purified by proprietary chromatographic technique, 17.7kDa. |
Recombinant EBV BFRF3 Protein [GST] |
|||
VAng-Lsx0120-inquire | Creative Biolabs | inquire | Ask for price |
Description: BFRF3 (EBV) (P14348) partial recombinant protein with GST tag expressed in E. coli. |
Recombinant EBV BMRF1 Protein [GST] |
|||
VAng-Lsx0121-inquire | Creative Biolabs | inquire | Ask for price |
Description: BMRF1 (EBV) (P03191) partial recombinant protein with GST tag expressed in E. coli. |
Inactivated EBV gp125 VCA Protein |
|||
VAng-Lsx04574-1mL | Creative Biolabs | 1 mL | EUR 423.6 |
Description: Epstein-Barr Virus (Strain P3HR1) gp125 VCA, inactivated antigen. |
Inactivated EBV gp125 VCA Protein |
|||
VAng-Lsx04574-25mL | Creative Biolabs | 25 mL | EUR 7318.8 |
Description: Epstein-Barr Virus (Strain P3HR1) gp125 VCA, inactivated antigen. |
EBV Glycoprotein 125 |
|||
DAG3085 | Creative Diagnostics | 25 ml | EUR 1966.8 |
Recombinant EBV p18 |
|||
DAGA-3074 | Creative Diagnostics | 100ug | EUR 1279.2 |
EBV BMRF1 [GST] |
|||
DAG1849 | Creative Diagnostics | 500 ug | EUR 3034.8 |
EBV antibody (VCA) |
|||
10-E40B | Fitzgerald | 200 ug | EUR 274.8 |
Description: Mouse monoclonal EBV antibody (VCA) |
EBV LMP2A Antibody |
|||
abx021712-025mg | Abbexa | 0.25 mg | EUR 1212 |
Inactivated EBV Antigen |
|||
VAng-Lsx0109-1mL | Creative Biolabs | 1 mL | EUR 1632 |
Description: EBV, natural antigen. |
Human EBNA1 Binding Protein 2 (EBNA1BP2) ELISA Kit |
|||
abx384822-96tests | Abbexa | 96 tests | EUR 1093.2 |
Epstein-Barr Virus (HHV-4) Mosaic EBNA1 Protein |
|||
20-abx260113 | Abbexa |
|
|
Mouse EBNA1 Binding Protein 2 (EBNA1BP2) ELISA Kit |
|||
abx389130-96tests | Abbexa | 96 tests | EUR 1093.2 |